Figure 4
From: Osteocrin ameliorates adriamycin nephropathy via p38 mitogen-activated protein kinase inhibition
FR167653, a p38 MAPK inhibitor, reduced ADR-induced albuminuria in OSTN KO mice. (a) Schematic of the experimental protocol. OSTN KO or control mice were injected intravenously with saline or ADR at 6 weeks of age. CT saline and CT ADR mice were used as reference groups shown in Fig. 1. (b) Urinary albumin creatinine ratio at weeks 5, 7, 8, 9 and 10 (n = 5–10 per group). (c) Schematic of the experimental protocol. OSTN KO or control mice were treated with FR167653 or vehicle and injected intravenously with ADR at 6 weeks of age. CT ADR and OSTN KO ADR mice were used as reference groups shown in Fig. 1 and Fig. 4a, respectively. (d) The BW at weeks 5, 6, 7, 8, 9 and 10 and right kidney weight, serum albumin, serum creatinine levels at 10 weeks of age (n = 6–10 per group). *P < 0.05, CT + V vs. OSTN KO + V, or CT + FR vs. OSTN KO + FR. **P < 0.01 by one-way ANOVA analysis. (e) Urinary albumin creatinine ratio at weeks 5, 7, 8, 9 and 10 (n = 6–10 per group). UACR: OSTN KO 284.8 ± 140.5 μg/mgCr vs. OSTN KO-FR 69.8 ± 8.2 μg/mgCr. Data are mean ± SD. *P < 0.05, **P < 0.01 and ***P < 0.001 by one-way ANOVA analysis. BW body weight, V vehicle, FR FR167653, CT control mice, OSTN KO OSTN KO mice, UACR urinary albumin creatinine ratio.
